[go: up one dir, main page]

PE20081878A1 - Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol - Google Patents

Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol

Info

Publication number
PE20081878A1
PE20081878A1 PE2008000434A PE2008000434A PE20081878A1 PE 20081878 A1 PE20081878 A1 PE 20081878A1 PE 2008000434 A PE2008000434 A PE 2008000434A PE 2008000434 A PE2008000434 A PE 2008000434A PE 20081878 A1 PE20081878 A1 PE 20081878A1
Authority
PE
Peru
Prior art keywords
indazole
hydroxyphenil
substituted
compounds derived
hydroxyphenyl
Prior art date
Application number
PE2008000434A
Other languages
English (en)
Inventor
Christopher Norbert Johnson
David G Jones
Xi Liang
David Timothy Macpherson
Aaron B Miller
Antoinette Naylor
Steven James Stanway
Andrew Kenneth Takle
Giancarlo Trani
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20081878A1 publication Critical patent/PE20081878A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE Ra, Rb Y Rc SON CADA UNO HALO, ALCOXI C1-C4, ALQUILO C1-C4, CF3, CN, ENTRE OTROS; m ES 0-3; n ES 0-1; p ES 0-4. SON COMPUESTOS PREFERIDOS: 1-(3-FLUORO-4-HIDROXIFENIL)-1H-INDAZOL-4-OL; 1-(3-FLUORO-4HIDROXIFENIL)-6-METI-1H-INDAZOL-4-OL; 1-(3,5-DIFLUORO-4-HIDROXIFENIL)-4-HIDROXI-1H-INDAZOL-6-CARBONITRILO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SE UNENAL RECEPTOR ERBETHA UTILES EN EL TRATAMIENTO DE DOLOR, ENFERMEDADES AUTOINMUNES, TRASTORNOS METABOLICOS O TRASTORNOS DEL APETITO
PE2008000434A 2007-03-07 2008-03-05 Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol PE20081878A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0704407.6A GB0704407D0 (en) 2007-03-07 2007-03-07 Compounds

Publications (1)

Publication Number Publication Date
PE20081878A1 true PE20081878A1 (es) 2009-03-05

Family

ID=37988543

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000434A PE20081878A1 (es) 2007-03-07 2008-03-05 Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol

Country Status (16)

Country Link
US (1) US7960563B2 (es)
EP (1) EP2118068A1 (es)
JP (1) JP2010520259A (es)
KR (1) KR20090118998A (es)
CN (1) CN101679288A (es)
AR (1) AR065605A1 (es)
AU (1) AU2008223850A1 (es)
BR (1) BRPI0808464A2 (es)
CA (1) CA2680109A1 (es)
CL (1) CL2008000647A1 (es)
EA (1) EA200970835A1 (es)
GB (1) GB0704407D0 (es)
MX (1) MX2009009581A (es)
PE (1) PE20081878A1 (es)
TW (1) TW200848025A (es)
WO (1) WO2008107455A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US8722894B2 (en) 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
MX2010002536A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-fenil-3,4,5,6-tetrahidro-2h, 1'h-[1,4]bipiridinil-2'-onas 1',3'-disubstituidas.
MX2010005110A (es) 2007-11-14 2010-09-09 Ortho Mcneil Janssen Pharm Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2.
GB0803017D0 (en) 2008-02-19 2008-03-26 Glaxo Group Ltd Compounds
BRPI0918055A2 (pt) 2008-09-02 2015-12-01 Addex Pharmaceuticals Sa derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato.
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
CA2744138C (en) 2008-11-28 2015-08-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2409006T3 (es) 2009-05-12 2013-06-24 Janssen Pharmaceuticals Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de los receptores mGluR2
SG176021A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
WO2012062759A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
SG11201405918XA (en) 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
PT3096790T (pt) 2014-01-21 2019-10-15 Janssen Pharmaceutica Nv Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso
EA202192105A3 (ru) 2014-02-04 2022-02-28 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
AU2019274580B2 (en) * 2018-05-23 2024-11-07 The Board Of Trustees Of The University Of Illinois Estrogen receptor beta ligands for the prevention and treatment of multiple sclerosis (MS) and other demyelinating, inflammatory and neurodegenerative diseases
CN110483403A (zh) * 2019-09-02 2019-11-22 南通大学 一种5-溴-4-甲氧基-1h-吲唑的合成方法
WO2021113436A1 (en) * 2019-12-04 2021-06-10 Arcus Biosciences, Inc. Inhibitors of hif-2alpha
KR20220155593A (ko) 2020-03-19 2022-11-23 아르커스 바이오사이언시즈 인코포레이티드 Hif-2알파의 억제제로서의 테트랄린 및 테트라히드로퀴놀린 화합물
US12145901B1 (en) 2021-09-17 2024-11-19 Arcus Biosciences, Inc. Process for preparing tetralin compounds

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0630367T3 (da) * 1992-03-09 2000-09-18 Zeneca Ltd Hidtil ukendte arylindazoler og deres anvendelse som herbicider
DE4236105A1 (de) 1992-10-26 1994-04-28 Hoechst Ag Arylboronsäuren als Vorprodukte zur Herstellung von Komponenten von Flüssigkristallmischungen
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
JPH0770078A (ja) * 1993-07-08 1995-03-14 Fuji Photo Film Co Ltd インダゾールの製造方法
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
DE10399017I2 (de) 1995-02-13 2006-04-27 Searle & Co Substituierte isoxazole zur behandlung von Entzündung
US5958710A (en) 1995-09-08 1999-09-28 Karo Bio Ab Orphan receptor
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
SI22713B (sl) 1996-04-12 2009-12-31 Searle & Co Substituirani benzensulfonamidni derivati kot predzdravila COX-2 inhibitorjev
SK283261B6 (sk) 1996-07-18 2003-04-01 Merck Frosst Canada & Co. / Merck Frosst Canada & Cie. Substituované pyridíny, farmaceutický prostriedok s ich obsahom a ich použitie
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
ATE281458T1 (de) 1997-09-05 2004-11-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
US6407261B1 (en) * 1998-04-17 2002-06-18 Eli Lilly And Company Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
TR200101208T2 (tr) 1998-11-03 2001-10-22 Glaxo Group Limited Seçici COX-2 inhibitörleri olarak pirazolopiridin türevleri
US6025683A (en) 1998-12-23 2000-02-15 Stryker Corporation Motor control circuit for regulating a D.C. motor
ATE261444T1 (de) 1999-02-27 2004-03-15 Glaxo Group Ltd Pyrazolopyridine
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
GB0021494D0 (en) 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
EP1640449A4 (en) * 2003-06-27 2009-03-25 Asahi Chemical Ind CELL DIFFERENTIATION INHIBITOR AGENT, CELL CULTURE METHOD USING THE SAME, CULTURE MEDIUM AND CULTIVATED CELL LINE
EP1647549A1 (en) 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents
TW200815361A (en) 2005-10-20 2008-04-01 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
JP2010520259A (ja) 2010-06-10
CL2008000647A1 (es) 2009-01-02
WO2008107455A1 (en) 2008-09-12
EA200970835A1 (ru) 2010-04-30
AR065605A1 (es) 2009-06-17
AU2008223850A1 (en) 2008-09-12
KR20090118998A (ko) 2009-11-18
GB0704407D0 (en) 2007-04-18
EP2118068A1 (en) 2009-11-18
CN101679288A (zh) 2010-03-24
MX2009009581A (es) 2009-09-16
US7960563B2 (en) 2011-06-14
CA2680109A1 (en) 2008-09-12
BRPI0808464A2 (pt) 2014-07-15
US20100087502A1 (en) 2010-04-08
TW200848025A (en) 2008-12-16

Similar Documents

Publication Publication Date Title
PE20081878A1 (es) Compuestos derivados de 1-(4-hidroxifenil sustituido)-4-ol-indazol
PE20110329A1 (es) Agonistas del receptor acoplado a la proteina g piperidinilo
EA200801738A1 (ru) Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
PE20110237A1 (es) Derivados de ciclohexilamida como antagonistas del receptor del factor de liberacion de corticotropina (crf-1)
ATE455110T1 (de) 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
GEP20135983B (en) 1-benzyl-3-hydroxymethylindazole derivatives and usage therein treatment of diseases based on mcp-1, cx3cr1 and p40 expression
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
NO20074567L (no) Glucagonreseptorantagoniser, fremstilling og terapeutisk anvendelse
CR11470A (es) Compuestos organicos
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
PE20050284A1 (es) Compuestos peptidicos como agonistas del receptor de melanocortina 4 (mc4)
MX2010009922A (es) Activadores de piridazinona glucocinasa.
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
CY1108230T1 (el) Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
PE20120218A1 (es) Compuestos para el tratamiento de trastornos metabolicos
PE20090592A1 (es) Nuevos derivados de piperazina-amida
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
GEP20156319B (en) Asymmetric ureas and medical uses thereof
PE20110928A1 (es) Derivados de 4-azetidinil-1-heteroaril-ciclohexanol como antagonistas de ccr2
MXPA05013856A (es) Agonistas del receptor sht2c para el tratamiento de diabetes y obesidad.
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
GEP20135913B (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1 and cx3cr1 expression

Legal Events

Date Code Title Description
FA Abandonment or withdrawal